Skip to content

Early screening of colorectal cancer based on plasma multi-omics combining with artificial intelligence: a multi-center, prospective study (R-E-C-O-M-M-E-N-D)

Early screening of colorectal cancer based on plasma multi-omics combining with artificial intelligence: a multi-center, prospective study (R-E-C-O-M-M-E-N-D)

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062422
Enrollment
Unknown
Registered
2022-08-05
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Healthy group:None
Advanced adenoma:None
Colorectal caner:None

Sponsors

Cancer Hospital, Chinese Academy of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years old and < 75 years old, regardless of gender; 2. Voluntarily participate and sign the informed consent form, and be able to cooperate with the entire research process; 3. Be able to provide sufficient and qualified blood samples for this study; 4. Patients with pathological diagnosis of colorectal cancer stage I-III (TNM staging according to AJCC 8th edition colorectal cancer staging system); 5. No previous cancer treatment, including chemotherapy, radiotherapy, targeted or immunotherapy, and any surgery treat.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or breastfeeding; 2. Currently diagnosed with a history of other tumors or cancers; 3. Persistent fever or receiving anti-inflammatory treatment within 14 days before blood samples are taken in this study; 4. Within 30 days before blood samples are taken in this study Received blood transfusion; 5. Received organ transplantation or previous non-autologous (allogeneic) bone marrow or stem cell transplantation; 6. Digestive tract bleeding, obstruction, perforation and any trauma or surgery within 3 months; 7. Poor physical condition, not suitable for extraction Blood samples; 8. Subjects who are judged by the investigator to be unsuitable to participate in this study for other reasons;

Design outcomes

Primary

MeasureTime frame
Pathological stage;

Secondary

MeasureTime frame
CEA;AFP;CA199;CA724;CA242;Age;Family history;

Countries

China

Contacts

Public ContactJianqiang Tang

Cancer Hospital, Chinese Academy of Medical Science

doc_tjq@hotmail.com+86 13661090036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026